Mitochondrial fission factor promotes cisplatin resistancein hepatocellular carcinoma

Acta Biochim Biophys Sin (Shanghai). 2022 Mar 25;54(3):301-310. doi: 10.3724/abbs.2022007.

Abstract

Hepatocellular carcinoma (HCC) is the most common primary liver tumor and one of the leading causes of cancer-related death worldwide. Chemotherapeutic agents/regimens such as cisplatin (DDP) are frequently used for advanced HCC treatment. However, drug resistance remains a major hindrance and the underline mechanisms are not fully understood. In this study, we investigated the expression pattern and function of mitochondrial fission factor (Mff) in cisplatin-resistant HCC. We found that Mff is highly expressed in cisplatin-resistant HCC tissues and cell lines. Knockdown of Mff suppresses cell proliferation and promotes cell apoptosis of HCC/DDP cells. In addition, knockdown of Mff sensitizes Huh-7/DDP cells to cisplatin treatment, inhibits cell proliferation, migration and invasion, and enhances cell apoptosis. Confocal imaging showed that knockdown of Mff inhibits the mitochondrial fission and downregulates the expression of GTPase dynamin-related protein 1 (Drp1) in cisplatin-resistant Huh-7/DDP cells. Moreover, xenograft tumor model revealed that knockdown of Mff sensitizes Huh-7/DDP xenograft tumor to cisplatin treatment . In summary, our findings suggest that Mff regulates mitochondrial Drp1 expression and promotes cisplatin resistance in HCC, which provides a potential therapeutic target for the treatment of resistant HCC.

Keywords: cisplatin resistance; dynamin-related protein 1; hepatocellular carcinoma; mitochondrial fission factor.

MeSH terms

  • Apoptosis / genetics
  • Carcinoma, Hepatocellular* / drug therapy
  • Carcinoma, Hepatocellular* / genetics
  • Cell Line, Tumor
  • Cisplatin / pharmacology
  • Cisplatin / therapeutic use
  • Drug Resistance, Neoplasm / genetics
  • Humans
  • Liver Neoplasms* / drug therapy
  • Liver Neoplasms* / genetics
  • Mitochondrial Dynamics / genetics
  • Mitochondrial Proteins / genetics
  • Mitochondrial Proteins / metabolism

Substances

  • Mitochondrial Proteins
  • Cisplatin

Grants and funding

This work was supported by the grants from the National Natural Science Foundation of China (No. 81671910), the Social Development Grant of Shaanxi Province (No. 2019SF-046), and the Xi′an International Medical Center Boost (No. 2020QN024).